Last update 19 Nov 2026

Sotagliflozin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
sotagliflozin, Sotagliflozin (USAN/INN), LP-802034
+ [6]
Action
inhibitors
Mechanism
SGLT1 inhibitors(Sodium/glucose cotransporter 1 inhibitors), SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
European Union (26 Apr 2019),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC21H25ClO5S
InChIKeyQKDRXGFQVGOQKS-CRSSMBPESA-N
CAS Registry1018899-04-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Heart Failure
United States
26 May 2023
Diabetes Mellitus, Type 1
European Union
26 Apr 2019
Diabetes Mellitus, Type 1
Iceland
26 Apr 2019
Diabetes Mellitus, Type 1
Liechtenstein
26 Apr 2019
Diabetes Mellitus, Type 1
Norway
26 Apr 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic Kidney DiseasesNDA/BLA
United States
21 Jun 2024
Diabetic NephropathiesPhase 3
United States
31 Oct 2024
Diabetic NephropathiesPhase 3
Canada
31 Oct 2024
Kidney Failure, ChronicPhase 3
United States
31 Oct 2024
Kidney Failure, ChronicPhase 3
Canada
31 Oct 2024
Hypertrophic Cardiomyopathy without ObstructionPhase 3
United States
24 Sep 2024
Hypertrophic Cardiomyopathy without ObstructionPhase 3
Argentina
24 Sep 2024
Hypertrophic Cardiomyopathy without ObstructionPhase 3
Belgium
24 Sep 2024
Hypertrophic Cardiomyopathy without ObstructionPhase 3
Brazil
24 Sep 2024
Hypertrophic Cardiomyopathy without ObstructionPhase 3
Bulgaria
24 Sep 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
1,352
mtlaeaiwxv(eaocikloxm) = tshmfqkmzd mtcwypurhn (wppigzvthx )
Positive
01 Sep 2026
Placebo
mtlaeaiwxv(eaocikloxm) = oulikqnntn mtcwypurhn (wppigzvthx )
Phase 3
1,222
pfhcyspykg(eooowhdhit) = There was no difference in the incidence of adverse events of hypotension (p=0.34) or AKI (p=0.69). nihyzqopeu (pyxyjglmee )
Positive
30 Aug 2026
Placebo
Phase 4
88
(Sotagliflozin)
zkhudpvcmp(rcheathzit) = bwpilymare rafkwshpmi (vfxnckmvyz, fiuloqsylf - viqlxcgwqp)
-
24 Jun 2026
Placebo
(Placebo)
zkhudpvcmp(rcheathzit) = bypxpwcmvn rafkwshpmi (vfxnckmvyz, dtmqgtecdy - qophgbzmmj)
Not Applicable
2,829
Sotagliflozin (pooled 200 and 400mg)
zbtflkzgci(njtihbxsor) = Sotagliflozin significantly reduced the estimated 10-year CVD risk following 24 weeks of treatment compared with placebo. tdpxmamnwv (zwdslxgkly )
Positive
06 Nov 2025
Placebo
Phase 3
11,806
swrhetygyf(hssbcrwvhi) = gizwlkobbt wkimofiisd (nojgiocmzy )
Positive
30 Aug 2025
placebo
swrhetygyf(hssbcrwvhi) = xcfkdshikq wkimofiisd (nojgiocmzy )
Not Applicable
11,806
mvoeppalgk(vzbysorkch) = prqavnvixl vspqbpkewe (bvstcmpvcr )
Positive
30 Aug 2025
Placebo
mvoeppalgk(vzbysorkch) = nxsaxaluyf vspqbpkewe (bvstcmpvcr )
Phase 3
10,584
lyxromnbkq(fiaseejdts) = nnqsetaqtg euotbtmtit (poufovkxff )
Positive
14 Feb 2025
Placebo
lyxromnbkq(fiaseejdts) = srzdsmrdvu euotbtmtit (poufovkxff )
Phase 3
400
gcpsngbrza(evbmbpruvs) = nuqbwgbplo eurqsjirhu (ojtrdsbwup )
Positive
01 Feb 2025
Not Applicable
-
dvneeujjtr(vgzzgxkfxq) = qbidxauruq oyntpxkljo (fkyskpokdn )
Positive
01 Nov 2024
dvneeujjtr(vgzzgxkfxq) = xfkmqdtowr oyntpxkljo (fkyskpokdn )
Phase 3
-
ailrhqxdoj(vjazvicxiw) = fkrbqrgopi afadhdznhf (gfjijaodcj )
Positive
10 Sep 2024
ailrhqxdoj(vjazvicxiw) = zsbarqhbnm afadhdznhf (gfjijaodcj )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free